

REFERÊNCIAS BIBLIOGRÁFICAS

1. Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. *Respir Res.* 2020; 21(1):1–10.
2. Travis WD, Costabel U, Hansell DM, King TE, Lynch DA, Nicholson AG, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. *Am J Respir Crit Care Med.* 2013;188(6):733–48.
3. Lederer DJ MF. Idiopathic Pulmonary Fibrosis. *N Engl J Med.* 2018;378:1811–23.
4. De Sadeleer LJ, Goos T, Yserbyt J, Wuyts WA. Towards the Essence of Progressiveness: Bringing Progressive Fibrosing Interstitial Lung Disease (PF-ILD) to the Next Stage. *J Clin Med.* 2020;9(6).
5. Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What's in a name? That which we call IPF, by any other name would act the same. *Eur Respir J* [Internet]. 2018;51(5):1–12. Available from: <http://dx.doi.org/10.1183/13993003.00692-2018>
6. Raghu G, Remy-jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. AMERICAN THORACIC SOCIETY Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults. 2022;205(9).
7. Wijsenbeek M, Cottin V. Spectrum of Fibrotic Lung Diseases. *N Engl J Med.* 2020;383(10):958–68.
8. RAGHU, Ganesh, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. *American journal of respiratory and critical care medicine*, 2018, 198.5: e44-e68
9. BADDINI-MARTINEZ, José, et al. Diretrizes brasileiras para o tratamento farmacológico da fibrose pulmonar idiopática. Documento oficial da Sociedade Brasileira de Pneumologia e Tisiologia baseado na metodologia GRADE. *Jornal Brasileiro de Pneumologia*, 2020, 46.
10. LYNCH, David A., et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. *The Lancet respiratory medicine*, 2018, 6.2: 138- 153.
11. Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370: 2071-82
12. King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. *N Engl J Med* 2014; 370: 2083-92.
13. Ley B, Swigris J, Day BM, et al. Pirfenidone reduces respiratory-related hospitalizations in idiopathic pulmonary fibrosis. *Am J Respir Crit Care Med* 2017; 196: 756-61.

14. Costabel U, Inoue Y, Richeldi L, et al. Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. *Am J Respir Crit Care Med* 2016; 193: 178-85.
15. Nathan SD, Albera C, Bradford WZ, et al. Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis. *Lancet Respir Med* 2017; 5: 33-41
16. Richeldi L, Cottin V, du Bois RM, et al. Nintedanib in patients with idiopathic pulmonary fibrosis: combined evidence from the TOMORROW and INPULSIS trials. *Respir Med* 2016; 113: 74-9
17. Wuyts WA, Cottin V, Spagnolo P, Wells AU. Pulmonary.
18. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. *N Engl J Med*. 2019; 381(18):1718–27.
19. George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, et al. Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. *Lancet Respir Med*. 2020;8(9):925-34.
20. Adegunsoye A, Oldham JM, Bellam SK, Montner S, Churpek MM, Noth I, et al. Computed Tomography Honeycombing Identifies a Progressive Fibrotic Phenotype with Increased Mortality across Diverse Interstitial Lung Diseases. *Ann Am Thorac Soc*. 2019;16(5):580-8.
21. Wong AW, Danoff SK. Providing Patient-Centered Care in Interstitial Lung Disease. *Clin Chest Med* [Internet]. 2021;42(2):337–46. Available from: <https://doi.org/10.1016/j.ccm.2021.03.003>
22. Kreuter M, Bendstrup E, Russell AM, Bajwah S, Lindell K, Adir Y, et al. Palliative care in interstitial lung disease: living well. *Lancet Respir Med* [Internet]. 2017;5(12):968–80. Available from: [http://dx.doi.org/10.1016/S2213-2600\(17\)30383-1](http://dx.doi.org/10.1016/S2213-2600(17)30383-1)
23. Gimenez A, Storrer K, Kuranishi L, Soares MR, Ferreira RG, Pereira CAC. Change in FVC and survival in chronic fibrotic hypersensitivity pneumonitis. *Thorax*. 2018;73(4):391–2.
24. Salisbury ML, Myers JL, Belloli EA, Kazerooni EA, Martinez FJ, Flaherty KR. Diagnosis and treatment of fibrotic hypersensitivity pneumonia: Where we stand and where we need to go. *Am J Respir Crit Care Med*. 2017;196(6):690–9.
25. Behr J, Prasse A, Kreuter M et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. *Lancet Respir Med*. 2021;9:476-486.
26. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled,

phase 2 trial. *Lancet Respir Med* [Internet]. 2020;8(2):147–57. Available from: [http://dx.doi.org/10.1016/S2213-2600\(19\)30341-8](http://dx.doi.org/10.1016/S2213-2600(19)30341-8)

27. Fischer A, Du Bois R. Interstitial lung disease in the connective tissue diseases. *Lancet* 2012; 380: 689–698
28. Solomon JJ, Fischer A. Connective tissue disease-associated interstitial lung disease: a focused review. *J Intensive Care Med* 2015; 30: 392–400.
29. Palm Ø, Garen T, Enger TB, et al. Clinical pulmonary involvement in primary Sjögren’s syndrome: prevalence, quality of life and mortality – a retrospective study based on registry data. *Rheumatology* 2013; 52: 173–179.
30. Kim EJ, Collard HR, King TE Jr. Rheumatoid arthritis-associated interstitial lung disease: the relevance of histopathologic and radiographic pattern. *Chest* 2009; 136: 1397–1405.
31. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis Rheum* 2010; 62: 2569–2581.
32. Johnson C. Recent advances in the pathogenesis, prediction, and management of rheumatoid arthritis-associated interstitial lung disease. *Curr Opin Rheumatol* 2017; 29: 254–259
33. Shaw M, Collins BF, Ho LA, et al. Rheumatoid arthritis-associated lung disease. *Eur Respir Rev* 2015; 24: 1–16.
34. 71 SPPT
35. Kiely P, Busby AD, Nikiphorou E, et al. Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts. *BMJ Open* 2019; 9: e028466
36. Singh JA, Saag KG, Bridges SL Jr, et al. 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. *Arthritis Care Res* 2016; 68: 1–25.
37. Holroyd CR, Seth R, Bukhari M, et al. The British Society for Rheumatology biologic DMARD safety guidelines in inflammatory arthritis – executive summary. *Rheumatology* 2019; 58: 220–226.
38. Flaherty KR, Wells AU, Cottin V, Devaraj A, Inoue Y, Richeldi L, et al. Nintedanib in progressive interstitial lung diseases: data from the whole INBUILD trial. *Eur Respir J*. 2022;59(3).
39. Tyndall AJ, Bannert B, Vonk M, et al. Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. *Ann Rheum Dis* 2010; 69: 1809–1815.
40. Hao Y, Hudson M, Baron M, et al. Early mortality in a multinational systemic sclerosis inception cohort. *Arthritis Rheumatol* 2017; 69: 1067–1077.

41. Ferri C, Valentini G, Cozzi F, et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. *Medicine* 2002; 81: 139–

153.

42. Nihtyanova SI, Schreiber BE, Ong VH, et al. Prediction of pulmonary complications and long-term survival in systemic sclerosis. *Arthritis Rheumatol* 2014; 66: 1625– 1635

43. Gelber AC, Manno RL, Shah AA, et al. Race and association with disease and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature. *Medicine* 2013; 92: 191–205.

44. Bouros D, Wells AU, Nicholson AG, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. *Am J Respir Crit Care Med* 2002; 165: 1581–1586.

45. Steen VD, Conte C, Owens GR, et al. Severe restrictive lung disease in systemic sclerosis. *Arthritis Rheum* 1994; 37: 1283–1289

46. Fischer A, Brown KK, Du Bois RM, et al. Mycophenolate mofetil improves lung function in connective tissue disease-associated interstitial lung disease. *J Rheumatol* 2013; 40: 640–646.

47. Nadashkevich O, Davis P, Fritzler M, et al. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. *Clin Rheumatol* 2006; 25: 205–212

48. Daoussis D, Melissaropoulos K, Sakellaropoulos G, et al. A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis- associated interstitial lung disease. *Semin Arthritis Rheum* 2017; 46: 625–631.

49. Khanna D, Denton CP, Lin CJF, et al. Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSSciate). *Ann Rheum Dis* 2018; 77: 212–220.

50. Distler O, Highland KB, Gahlemann M, et al. Nintedanib for systemic sclerosis- associated interstitial lung disease. *N Engl J Med* 2019; 380: 2518–2528.

51. Borie R, Schneider S, Debray MP, et al. Severe chronic bronchiolitis as the presenting feature of primary Sjogren’s syndrome. *Respir Med* 2011; 105: 130–136.

52. Stojan G, Baer AN, Danoff SK. Pulmonary manifestations of Sjogren’s syndrome. *Curr Allergy Asthma Rep* 2013; 13: 354–360.

53. Sharp GC, Irvin WS, Tan EM, et al. Mixed connective tissue disease – an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen (ENA). *Am J Med* 1972; 52: 148–159

54. Vegh J, Szodoray P, Kappelmayer J, et al. Clinical and immunoserological characteristics of mixed connective tissue disease associated with pulmonary arterial hypertension. *Scand J Immunol* 2006; 64: 69–76.
55. Livro práticas pneumológicas SBPT 2022
56. Azuma A, Ph D, Brown KK, Costabel U, Cottin V, Ph D, et al. Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis. 2014;1–12.
57. Boehringer Ingelheim Pharmaceuticals Prescribing Information. Ofev Full Prescribing Information. Ofev. 2014;1–18.
58. King TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A Phase 3 Trial of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. *N Engl J Med [Internet]*. 2014;370(22):2083–92.
59. Raghu G, Rochweg B, Zhang Y, Garcia CAC, Azuma A, Behr J, et al. An official ATS/ERS/JRS/ALAT clinical practice guideline: Treatment of idiopathic pulmonary fibrosis: An update of the 2011 clinical practice guideline. *Am J Respir Crit Care Med*. 2015;192(2):e3–19.

Autores

- Déborah dos Reis Estrella – Hospital Júlia Kubitschek/Fhemig
- Eliane Mancuzo – Hospital das Clínicas da UFMG
- Tarciane Aline Prata – Hospital Júlia Kubitschek/Fhemig
- Gediel Cordeiro Júnior – Hospital Júlia Kubitschek/Fhemig